Maryland State Retirement & Pension System lessened its stake in shares of Organon & Co. (NYSE:OGN – Free Report) by 2.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 109,035 shares of the company’s stock after selling 2,440 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Organon & Co. were worth $2,257,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Prevail Innovative Wealth Advisors LLC purchased a new stake in shares of Organon & Co. during the 4th quarter valued at about $3,336,000. Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in shares of Organon & Co. during the 4th quarter valued at about $1,850,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Organon & Co. during the 1st quarter valued at about $6,284,000. Friedenthal Financial bought a new position in shares of Organon & Co. in the 2nd quarter worth approximately $769,000. Finally, Allianz Asset Management GmbH lifted its stake in shares of Organon & Co. by 156.5% in the 4th quarter. Allianz Asset Management GmbH now owns 1,900,554 shares of the company’s stock worth $27,406,000 after purchasing an additional 1,159,519 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group increased their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd.
Organon & Co. Stock Performance
Shares of NYSE:OGN traded up $0.04 during trading on Friday, hitting $22.35. The company’s stock had a trading volume of 1,446,988 shares, compared to its average volume of 2,223,694. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $23.10. The firm has a market cap of $5.75 billion, a price-to-earnings ratio of 5.46, a P/E/G ratio of 0.90 and a beta of 0.85. The company has a 50-day moving average of $20.93 and a 200-day moving average of $19.80. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17.
Organon & Co. (NYSE:OGN – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The company had revenue of $1.61 billion for the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter last year, the business earned $1.31 EPS. The firm’s revenue was down .1% compared to the same quarter last year. On average, sell-side analysts expect that Organon & Co. will post 4.14 earnings per share for the current year.
Organon & Co. Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 12th. Shareholders of record on Friday, August 16th will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 5.01%. The ex-dividend date of this dividend is Friday, August 16th. Organon & Co.’s payout ratio is 27.38%.
Organon & Co. Profile
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Read More
- Five stocks we like better than Organon & Co.
- How to Choose Top Rated Stocks
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- What is the Shanghai Stock Exchange Composite Index?
- Why Dell Can Continue Winning in AI and Beyond
- Basic Materials Stocks Investing
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.